Argatroban for anticoagulation in continuous renal replacement therapy

Critical Care Medicine

Volumn 37, Issue 1, 2009, Pages 105-110

  Link, Andreas ^a   Girndt, Matthias ^a   Selejan, Simina ^a   Mathes, Alexander ^a   Böhm, Michael ^a   Rensing, Hauke ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Argatroban; Continuous renal replacement therapy; Heparininduced thrombocytopenia II syndrome; Multiple organ failure

Indexed keywords

ARGATROBAN; HEPARIN; INDOCYANINE GREEN; LEPIRUDIN; NITROGEN; UREA; ANTICOAGULANT AGENT; PIPECOLIC ACID DERIVATIVE;

ACUTE KIDNEY FAILURE; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MALE; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEADY STATE; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL; UNIVERSITY HOSPITAL; UREA NITROGEN BLOOD LEVEL; CHEMICALLY INDUCED DISORDER; CRITICAL ILLNESS; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY;

AGED; ANTICOAGULANTS; CRITICAL ILLNESS; FEMALE; HEPARIN; HUMANS; KIDNEY FAILURE, ACUTE; MALE; PIPECOLIC ACIDS; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; THROMBOCYTOPENIA;

EID: 59649086734     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181932394     Document Type: Article

References (29)

1. Buchardi H: History and development of continuous renal replacement techniques. Kidney Int Suppl 1998; 66:S120-S124
2. Bellomo R, Ronco C: Continuous renal replacement therapy in intensive care unit. Intensive Care Med 1999; 25:781-789
3. Keeling D, Davidson S, Watson H: The management of heparin-induced thrombocytopenia. Br J Haematol 2006; 133:259-269
4. Oudemans-van Straaten MH, Wester JPJ, de Pont ACJM, et al: Anticoagulation strategies in continuous renal replacement therapy: Can the choice be evidence based? Intensive Care Med 2006; 32:188-202
5. Magnani HN: Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70:554-561
6. Polkinghorne KR, McMahon LP, Becker GJ: Pharmocokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable hemodialysis patients. Am J Kidney Dis 2002; 40:990-995
7. Lindhoff-Last E, Betz C, Bauersachs R: Use of a low-molecular-weight heparinoid (danap-aroid sodium) for continuous renal replacement therapy in intensive care patients. Clin Appl Thromb Hemost 2001; 7:300-304
8. Fischer KG: Hirudin in renal insufficiency. Semin Thromb Hemost 2002; 28:467-482
9. Eichler P, Friesen HJ, Lubenow N, et al: Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT, and clinical relevance. Blood 2000; 96:2373-2378
10. Kern H, Ziemer S, Kox WJ: Bleeding after intermittent or continuous r-hirudin during CVVH. Intensive Care Med 1999; 25: 1311-1314
11. Muhl E, Siemens HJ, Kujath P, et al: Therapy and monitoring of heparin-induced thrombocytopenia type II in critically ill patients during continuous venovenous hemodiafiltration: Comparison of aPTT and ecarin clotting time for monitoring of r-hirudin therapy. J Intensive Care 2002; 17:34-40
12. Matsuo T, Yamada T, Yamanashi R, et al: Anticoagulant therapy with MD805 of a hemodialysis patient with heparin-induced thrombocytopenia. Thromb Res 1990; 58:663-666
13. Koide M, Yamamoto S, Matsuo M, et al: Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis. Nephrol Dial Transplant 1995; 10:2137-2140
14. Murray PT, Reddy BV, Grossman EJ, et al: A prospective comparison of three argatroban treatment regimes during hemodialysis in endstage renal disease. Kidney Int 2004; 66: 2446-2453
15. Koster A, Buz S, Hetzer R, et al: Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: First results from the ARGE03 trial. J Thorac Cardiovasc Surg 2006; 132:699-700
16. Knaus W, Draper E, Wagner D, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-832
17. Le Gall JR, Lemeshow S, Saulnier F: A new simplified acute physiology score (SAPS II) based on a European/North American multi-center study. JAMA 1993; 270:2957-2963
18. Kimura S, Yoshioka T, Shibuya M, et al: Indocyanine green elimination rate detects hepatocellular dysfunction early in septic shock and correlates with survival. Crit Care Med 2001; 29:1159-1163
19. Sakka SG, Reinhart K, Meier-Hellmann A: Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest 2002; 122:1715-1720
20. Arpino PA, Hallisey RK: Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother 2004; 38:25-29
21. Williamson DR, Boulanger I, Tardif M, et al: Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 2004; 24:409-414
22. Levine RL, Hurstling MJ, McCollum D: Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006; 129:1167-1175
23. Beiderlinden M, Treschan TA, Gorlinger K, et al: Argatroban anticoagulation in critically ill patients. Ann Pharmacother 2007; 41: 749-754
24. Reichling 33, Kaplan MM: Clinical use of serum enzymes in liver disease. Dig Dis Sci 1988; 33:1601-1614
25. Shakil AO, Kramer D, Mazariegos GV, et al: Acute liver failure: Clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl 2000; 6:163-169
26. Sakka SG: Assessing liver function. Curr Opin Crit Care 2007; 13:207-214
27. Sakka SG, Reinhart K, Meier-Hellmann A: Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest 2002; 122: 1715-1720
28. Lewis BE, Wallis DE, Berkowitz SD, et al: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103:1838-1843
29. Alving BM: How I treat heparin-induced thrombocytopenia and thrombosis. Blood 2003; 101:31-37